Clinical trial
Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat…
NCT00363415 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00363415 |
|---|---|
| Title | Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer |
| Official title | A Randomized Phase 3 Trial of Alimta (Pemetrexed) and Carboplatin Versus Etoposide and Carboplatin in Extensive-Stage Small Cell Lung Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | pemetrexed, etoposide, carboplatin |
| Enrollment | 908 |
| Start date | Aug 1, 2006 |
| Primary completion | Jun 1, 2008 |
| Completion | Jun 1, 2008 |
| First posted | Aug 15, 2006 |
| Last update posted | Oct 28, 2009 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, China, France, Germany, Greece, Hungary, India, Italy and 14 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: